Theralase Technologies Inc. V.TLT

Timeframe to complete ?

[Oden6570]

I would expect that the vaccine front offers many oppurtunities to partner or licence deals. Would a topical ointment require the same vigor of clinical trials or could this happen far quicker ?



Arkady Mandel, chief scientific officer, Theralase, stated, "Theralase is very excited about the acceptance of our publication to Heliyon. This publication substantiates the years of work that the team has undertaken to demonstrate that Ruvidar is an effective technology to inactivate numerous viruses both with and without the presence of light and can be used as a strong antiviral platform in the production of vaccines in the near future, subject to completion of animal and toxicology testing. As a result, the Theralase lab in Toronto will focus on using Ruvidar to research and develop a topical therapeutic to mitigate the impact of herpes virus lesions. I look forward to supporting the implementation of this technology at the commercial level."

Roger DuMoulin-White, Pro.Dir., president and chief executive officer, Theralase, stated, "The small molecule Ruvidar has been preclinically proven to kill bacteria and various cancer cells and clinically proven to kill bladder cancer cells. It is currently under preclinical evaluation in the destruction of brain cancer, lung cancer and various blood-based cancers, such as: leukemia, lymphoma and multiple myeloma. Based on the latest research detailing Ruvidar's success in the destruction of various viruses, the company has gained consensus from the National Microbiology Laboratory to direct its research away from the Covid-19 virus vaccine to develop this technology for an avian influenza vaccine."



Theralase Technologies’ lead compound, Ruvidar effective in virus inactivation